1. The Acne Landscape Is Evolving

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Background

4. Treatment for Acne Is Growing

5. Psychosocial and QoL Impact of Patients With Acne

6. Severity of Acne and Impact on Patients

7. Determining Acne Severity

8. Guideline Recommended Treatments for Moderate to Severe Acne

9. Individualizing Treatment for Patients With Moderate to Severe Acne

10. Tips to Increase Adherence to Acne Treatment

11. New Topical Retinoid Tretinoin 0.05% Lotion

12. Evaluating Patient Satisfaction

13. Results Tretinoin 0.05% Lotion

14. Relevance to Clinical Practice

15. New Topical Antibiotic 4% Minocycline Foam

16. Efficacy 4% Minocycline Foam Absolute Change in Inflammatory Lesion Count at Week 12

17. Efficacy 4% Minocycline Foam Proportion of Patients Achieving IGA = Clear/Almost Clear

18. Safety Minocycline 4% Foam

19. New Retinoid With a New MOA Trifarotene 50 μg/g Cream

20. PERFECT 1 and 2 Efficacy Endpoints Trifarotene 50 μg/g Cream

21. Results: Facial IGA and Truncal PGA Trifarotene 50 μg/g Cream

22. Safety Trifarotene 50 μg/g Cream

23. New Topical Anti-Androgen Clascoterone 1% Cream

24. Phase 3 Baseline Lesion Counts & IGA Scores Clascoterone 1% Cream

25. Phase 3 Efficacy Results Clascoterone 1% Cream

26. Clascoterone, 1% Cream Acne Phase 3 Studies IGA Treatment Success at Week 12: IGA (0) or (1)

27. Clascoterone, 1% Cream: Phase 3 Studies Absolute Reduction of Non-Inflammatory Lesion Count Week 12

28. New Oral Antibiotic Sarecycline

29. Phase 3 Study Design Sarecycline

30. Efficacy Sarecycline

31. Safety Sarecycline

32. Which Patients Are Good Candidates for These Medications?

33. Concluding Remarks

34. Abbreviations